Janus Henderson Group PLC Purchases 873 Shares of Enovis Co. (NYSE:ENOV)

Janus Henderson Group PLC raised its position in shares of Enovis Co. (NYSE:ENOV) by 0.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 499,185 shares of the company’s stock after acquiring an additional 873 shares during the quarter. Janus Henderson Group PLC’s holdings in Enovis were worth $21,903,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. grew its holdings in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in Enovis by 19.5% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company’s stock valued at $677,000 after purchasing an additional 2,518 shares during the period. Assenagon Asset Management S.A. bought a new position in Enovis during the fourth quarter valued at $437,000. Tributary Capital Management LLC grew its holdings in Enovis by 33.9% during the fourth quarter. Tributary Capital Management LLC now owns 566,089 shares of the company’s stock valued at $24,840,000 after purchasing an additional 143,258 shares during the period. Finally, Park Avenue Securities LLC grew its holdings in Enovis by 12.5% during the fourth quarter. Park Avenue Securities LLC now owns 11,988 shares of the company’s stock valued at $526,000 after purchasing an additional 1,333 shares during the period. 98.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of analyst reports. JMP Securities cut their price target on Enovis from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Friday, May 9th. Needham & Company LLC cut their price target on Enovis from $64.00 to $57.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, Canaccord Genuity Group cut their price target on Enovis from $75.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Enovis has an average rating of “Moderate Buy” and a consensus target price of $58.00.

Enovis Price Performance

NYSE:ENOV opened at $35.86 on Friday. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -16.37 and a beta of 1.79. Enovis Co. has a 52-week low of $29.32 and a 52-week high of $53.31. The stock has a fifty day moving average of $35.16 and a 200 day moving average of $41.45. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.07. The company had revenue of $558.83 million during the quarter, compared to analyst estimates of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the company earned $0.50 earnings per share. On average, research analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.